^
Association details:
| Biomarker: | BRAF V600 |
|---|---|
| Cancer: | Melanoma |
| Drug: | Zolinza (vorinostat) (HDAC inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
829P - A proof of concept study of sequential treatment with the HDAC inhibitor vorinostat plus BRAF and MEK inhibitors in BRAFV600 mutated melanoma
Published date:
09/05/2022
Excerpt:
25 patients (16M/9F, median age 56 years) with advanced, progressive BRAFi/MEKi resistant BRAF V600 melanoma have initiated treatment with vorinostat. 21 patients were evaluable for response. Best objective response: 4 PR (confirmed in 3 pts, duration of response 6.2, 9.3 and 18.6 months), 4 SD (confirmed in 1 pt, duration 9.3 months) and 13 PD.
Trial ID:
